Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02982915 · ClinicalTrials.gov registry record · Phase 1
Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty
A Phase 1 study, sponsored by Longeveron.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT02982915 is a Phase 1 study that has completed, run by Longeveron. The registered enrollment target is 62 participants.
The verdict
NCT02982915, a Phase 1 study, has completed, sponsored by Longeveron.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response.
Interventions
- BIOLOGICAL Fluzone High Dose Vaccine
- BIOLOGICAL Longeveron Mesenchymal Stem Cells (LMSCs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2016-11 |
| Est. Completion | 2022-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02982915
The ClinicalTrials.gov registry entry for NCT02982915 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Longeveron, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluzone High Dose Vaccine is the first listed.
NCT02982915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02982915 about?
NCT02982915 is a clinical study titled "Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty". This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response.
What is the current status of trial NCT02982915?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2016-11. Estimated completion is 2022-09.
What interventions are being tested in trial NCT02982915?
The interventions under investigation include: Fluzone High Dose Vaccine (BIOLOGICAL), Longeveron Mesenchymal Stem Cells (LMSCs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02982915?
This trial is sponsored by Longeveron, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.